-
admin
Posts
Global Aerospace’s Annual Jetstream Publication Provides An Introduction to Litigation Funding
Litigation Funding: A Wolf in Sheep’s Clothing? Insights from Global Aerospace’s Annual Jetstream Publication Morris Plains, NJ, June 12, 2026 (GLOBE NEWSWIRE) — Imagine this...
HorseWood Claims Evaluated: The Horse Gelatin Trick for Natural Male Enhancement Support
Horsewood 7-Herb Formula: Tongkat Ali 100:1, Horny Goat Weed, Saw Palmetto, Wild Yam, Nettle, Sarsaparilla, Boron Ingredients and Guarantee Largo, FL, June 12, 2026 (GLOBE...
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes Accelerated approval in children...
Riding the Momentum of APEC’s China Year: Telling China’s Story Visits Hanyang University, Engages Korean Youth on the Future of Asia-Pacific Cooperation
SHENZHEN, China, June 13, 2026 /PRNewswire/ — The 33rd APEC Economic Leaders’ Meeting is scheduled to be held in Shenzhen, China, in November 2026. Building on...
Luxel Corporation Appoints KOS, Inc. as Exclusive Distributor in South Korea
FRIDAY HARBOR, Wash., June 13, 2026 /PRNewswire/ — Luxel Corporation, a global leader in the design and manufacture of ultrathin freestanding polymer and metallized optical bandpass...
Bitmine Immersion Technologies Announces Initial Dividends and NYSE Listing for Series A Preferred Stock
Bitmine’s Board of Directors declares initial cash dividends on the Company’s 9.50% Series A Perpetual Preferred Stock Series A Preferred Stock approved for listing on...
Zodiac Partners II, LLC Reaffirms its Previously Announced $46 million Tender Offer to Acquire Destination XL Group, Inc. for $0.82 Per Share in Cash
West Palm Beach FL, June 12, 2026 (GLOBE NEWSWIRE) — In light of the recent announcement by Destination XL Group, Inc. (“DXLG” or “DXL”) that...
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
– JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors – – Selective JAK V617F inhibitor, CGT1145, on...
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) — Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory...
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
MINNEAPOLIS, June 12, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of...
